Avoro Capital Advisors LLC
Institutional investor · Portfolio as of Q4 2025
Top Holdings34 positions
Stock | Shares | Value | Weight | Avg Buy | Est. P&L | Held | Conviction |
|---|---|---|---|---|---|---|---|
UNITED THERAPEUTICS CORP | 2.6M | $1.3B | 12.5% | $228.72 | +116.94% | 21 qtrssince 2020-Q4 | Increased 79 |
ASCENDIS PHARMA A/S | 5.1M | $1.1B | 10.7% | $129.53 | +61.61% | 19 qtrssince 2021-Q2 | Increased 63 |
MADRIGAL PHARMACEUTICALS INC | 1.8M | $1.1B | 10.3% | $157.20 | +271.34% | 28 qtrssince 2019-Q1 | Decreased 0 |
ARGENX SE - ADR | 990,000 | $832.5M | 8.2% | $224.78 | +272.77% | 28 qtrssince 2019-Q1 | Unchanged 0 |
Krystal Biotech, Inc. | 2.9M | $712.2M | 7.0% | $104.94 | +136.20% | 17 qtrssince 2021-Q4 | Increased 65 |
ARROWHEAD PHARMACEUTICALS IN | 10.6M | $705.4M | 6.9% | $27.02 | +148.89% | 11 qtrssince 2023-Q2 | Decreased 0 |
KYMERA THERAPEUTICS INC | 7.5M | $581.6M | 5.7% | $39.66 | +96.98% | 18 qtrssince 2021-Q3 | Increased 72 |
STRUCTURE THERAPEUTICS INC | 6.6M | $455.9M | 4.5% | $34.37 | +97.20% | 2 qtrssince 2025-Q3 | Increased 72 |
| 5.5M | $393.5M | 3.9% | $28.19 | — | 23 qtrssince 2020-Q2 | Decreased 0 | |
CENTESSA PHARMACEUTICALS PLC | 14.6M | $364M | 3.6% | $21.02 | +17.68% | 4 qtrssince 2025-Q1 | Increased 75 |
CELCUITY INC | 3.1M | $310.3M | 3.0% | $99.92 | 0.00% | 1 qtr | New 87 |
APELLIS PHARMACEUTICALS INC | 12.2M | $307M | 3.0% | $42.79 | -41.02% | 20 qtrssince 2021-Q1 | Unchanged 0 |
VERA THERAPEUTICS INC | 5.9M | $298.2M | 2.9% | $40.72 | +25.67% | 8 qtrssince 2024-Q1 | Decreased 0 |
SPDR S&P BIOTECH ETF | 2.1M | $256.1M | 2.5% | $121.67 | +29.37% | 1 qtr | New 81 |
XENON PHARMACEUTICALS INC | 5.4M | $243.1M | 2.4% | $21.49 | +105.34% | 28 qtrssince 2019-Q1 | Increased 54 |
TERNS PHARMACEUTICALS INC | 4.4M | $175.7M | 1.7% | $40.59 | 0.00% | 1 qtr | New 71 |
REVOLUTION MEDICINES INC | 2.2M | $172.8M | 1.7% | $79.67 | 0.00% | 1 qtr | New 71 |
uniQure N.V. | 6.2M | $147.2M | 1.4% | $23.87 | -0.37% | 5 qtrssince 2024-Q4 | Increased 64 |
SOLENO THERAPEUTICS INC | 2.9M | $134.3M | 1.3% | $47.38 | -2.30% | 9 qtrssince 2023-Q4 | Increased 55 |
OCULAR THERAPEUTIX INC | 10.8M | $130.8M | 1.3% | $9.98 | +22.20% | 8 qtrssince 2024-Q1 | Increased 51 |
Avoro Capital Advisors LLC manages $10.2B across 34 positions as of Q4 2025. Top holdings: UTHR (12.5%), ASND (10.7%), MDGL (10.3%). Fund DNA: Balanced Allocator. HoldingsIntel Rating: 1.5/5.0.
Active quarter - 11 new positions, 8 exits, 10 increased. Top move: CELC (NEW, conviction 87). Portfolio: $10.2B across 34 positions.
Top holdings by portfolio weight
Portfolio allocation by GICS sector
Behavioral investing profile
Position Outcomes
Best and worst performing positions by estimated return
Top Winners
Top Losers
Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.
Similar Funds
Funds with similar investing DNA
Explore More
Accumulation Streaks
Positions with 2+ consecutive quarters of increases - persistent directional conviction.
Continue exploring
Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer